We describe the transfer of a different autoimmune thyroid disorder by bone marrow transplantation. The donor had euthyroid Graves' disease after treatment with antithyroid drugs and stable oxopthalmos, with persistent thyroid autoantibodies. One year after bone marrow transplant, the recipient developed atrophic autoimmune hypothyroidism. Six months later the donor developed transient subclinical hypothyroidism followed by clinical hyperthyroidism. In both recipient and donor the presence of thyrotropin (TSH)-binding inhibitory immunoglobulins was documented. Although TSH receptor antibodies usually act as a TSH agonist causing thyrotoxicosis, they can also can act as a TSH antagonist causing primary hypothyroidism. This case may be an example of how the same antibody can act as an agonist in the donor and an antagonist in the bone marrow recipient, causing two different autoimmune disorders: primary hypothyroidism in the recipient and Graves' disease in the donor. Bone Marrow Transplantation (2000) 26, 1217-1220.
Experiments with animal models have shown that various autoimmune diseases can be transferred to normal healthy animals by allogeneic bone marrow transplantation (BMT), particularly after conditioning therapy with total body irradiation. 1 In addition, transfer of different autoimmune diseases has been described in humans after BMT. In these cases of post-transplant adoptive autoimmunity, a clone of donor lymphocytes programmed to produce autoantibodies and/or a cytotoxic response may be transferred from donor to recipient. 2 Human autoimmune thyroid disorders -Graves' disease (GD) and Hashimoto's thyroiditis (HT) -are characterized by reactivity to self thyroid antigens, which may result in destructive inflammatory or anti-receptor autoimmune diseases. 3 Immunological disturbances in autoimmune thyroid disorders are not solely limited to the thyroid gland, as the orbit and occasionally the skin can also be affected. 3 This multiorgan involvement and the association of autoimmune thyroid disorders with other autoimmune diseases suggest a generalized immune disregulation. 4 At least two types of anti-receptor antibodies directed against TSH-receptor (TRAbs) exist in the sera of patients with autoimmune thyroid disease. TRAbs usually act as TSH agonists causing thyrotoxicosis in GD (thyroid stimulating antibodies: TSAb). In addition, TRAbs with TSH antagonist activity have been found in the sera of some patients with primary hypothyroidism. These antibodies have been referred to as thyroid stimulating-blocking antibodies (TSBAb), and presumably cause thyroid dysfunction and atrophy. 5 It has been generally known that the appearance of TSBAb causes hypothyroidism in patients with Graves' hyperthyroidism who have been previously treated with antithyroid drugs. 6, 7 In the literature, however, there have been no cases of this transition from hyper to hypothyroidism in donors and/or recipients after BMT. In this report, we describe a patient who developed primary hypothyroidism following BMT from a donor with treated GD, who also subsequently developed transient primary hypothyroidism. In both cases the presence of TSH-binding inhibitory immunoglobulins (TBII) was documented.
Case reports

Recipient
A 23-year-old Caucasian man, was diagnosed with acute lymphoblastic leukemia, m-bcr-abl positive, in September 1997. He was treated with a BFM-like chemotherapeutic regimen (PETHEMA-93) and obtained a complete remission. In February 1998, he received an allogeneic BMT from his HLA fully compatible and ABO-identical sister. The recipient had normal levels of T 4 and TSH, and negative anti-thyroid antibodies. Cyclophosphamide (60 mg/kg/day) for 2 days (days −6 and −5) was given, 12 Gy total body irradiation was fractionated in four daily doses of 3 Gy (days −4, −3, −2 and −1). The bone marrow was not T cell depleted, and the infusion contained 3.8 × 10 8 MNCs per kilogram. Methotrexate and cyclosporin A (CsA) were used for graft-versus-host disease (GVHD) prophylaxis. On day +22, he developed acute GVHD grade III, which promptly reversed with corticosteroid therapy. Two months after BMT, CMV antigenemia was detected, and he received gancyclovir and foscarnet. His subsequent course was complicated by transient bone marrow hypoplasia and thoracic zoster. Five months after BMT, T 4 and TSH levels were normal (Table 1) . Autoantibodies including anti-thyroid, ANA, anti-DNA, SSA, SSB, RNP, Sm, and Jo-1 were undetectable. He did not develop any sign of chronic GVHD, and CsA was interrupted 6 months after BMT. At month +8, immunological reconstitution was normal, with a lowered CD4/CD8 ratio, and low levels of antithyroid antibodies were detected (1:400). In month +10, the recipient complained of weakness and somnolence. The thyroid gland was not enlarged or tender. There were no abnormal opthalmic findings. Thyroid function tests showed primary hypothyroidism and low levels of TRAb were detected by TBII (TSH-binding inhibitory immunoglobulins assayed by a radioreceptor assay using a commercial kit: Izasa, Spain) ( Table 1 ). Treatment with thyroxine was started. At that time chimerism was complete in mononuclear and polymorphonuclear cells, as detected by PCR study of VNTR regions, and PCR of IgH region did not detect rearrangement in peripheral mononuclear cells. From month +9, an increase in hepatic enzymes was detected. EBV, adenovirus, RSV, HBV and HCV were excluded as causative agents. A liver biopsy was not performed. Hepatic enzymes progressively reduced and normalized at month +15. At month +16, thyroid hormone therapy was stopped and he was re-evaluated after 2 months with no treatment. Further thyroid functions tests revealed subclinical hypothyroidism (Table 1) . At the same time, the patient developed generalized vitiligo. Two years after BMT he remains asymptomatic on thyroid hormone therapy, without signs of disease. He is in complete molecular remission from his leukemia and is totally free of chronic GVHD. Table 1 Thyroid function tests and autoantibody levels before and after bone marrow transplant 
Sibling donor
The donor was his MHC-identical 19-year-old sister. Two years previously she presented with symptoms and signs of hyperthyroidism and Graves' opthalmopathy grade II classified following the American Thyroid Association (NO-SPECS classification), with high levels of antimicrosomal antibodies (AMA). She received anti-thyroid therapy for 1. years and reverted to a euthyroid status with persistent antimicrosomal antibodies at low titers. Six months after remission, at the time of the BMT her opthalmopathy remained stable at grade II of the NO-SPECS classification, her thyroid function tests were normal on no therapy, and her thyroid antibodies continued positive at low titers (Table 1 ). After BMT she remained asymptomatic, with no goiter, stable opthalmopathy and normal thyroid function tests. At month +15 after BMT, her thyroid function tests were compatible with subclinical hypothyroidism, with high levels of antimicrosomal antibodies and elevation of TBII (Table 1) . A thyroid scan ( 99m TcO − 4 ) showed a normal thyroid with normal uptake. On month +18 she started to recover from the hypothyroidism and on month +21 she relapsed with clinical hyperthyroidism with a grade II goiter (Table 1) .
Discussion
It is now well accepted that donor-derived immunity can be transferred by allogeneic BMT. 2 In humans, the transfer of autoimmune thrombocytopenic purpura, glomerulonephritis, 8 myasthenia gravis, 8 GD 9,10 and autoimmune hypothyroidism 9, 11 from BMT donors to recipients who have undergone BMT for hematological diseases has been reported. In previous reports of transfer of autoimmune thy-roid disorders, donors with hyper and hypothyroidism have transferred hyper and hypothyroidism respectively to recipients by BMT (see Table 2 for review of literature). In addition, post-transplant adoptive autoimmune thyroid disorders have been reported after transplantation of allogeneic CD34
+ selected peripheral blood cells 16 and after stem cell transplantation. 17 In our case, the donor was in a euthyroid state during BMT with persistent opthalmopathy and low titers of antibodies after treatment of hyperthyroidism with antithyroid drugs 1. years before. One year after BMT, the recipient developed atrophic hypothyroidism and 6 months later the donor developed transient subclinical hypothyroidism followed by clinical hyperthyroidism. In this case, it is probable that donor-derived autoimmunity was responsible for the hypothyroidism in the recipient and this could be an example of how GD can not only evolve to hypothyroidism in the same patient, but how it can also be transferred as hypothyroidism to the bone marrow recipient.
The likely mechanism of the hypothyroidism is that the recipient had received a clone of donor lymphocytes programmed to be cytotoxic for autologous thyroid cells and/or to produce thyroid autoantibodies that may be either thyroid stimulating or thyroid blocking. After allogeneic BMT the immune system of the host is effectively eliminated by pretransplantation conditioning, and immunity in long-term allogeneic BMT survivors is mostly of donor origin. 2 In the short term after BMT there is adoptive transfer of antigenspecific memory B cells from the donor, that can be enhanced by re-immunizing the donor early enough before the BMT. 18 It is not clear whether activated donor B or T cell clones, such as those involved in autoimmune diseases, have a survival advantage in the impaired host immune system. In this regard, an equal chance of transferring abnormal and normal clones to specific allergens after BMT has been reported. 19 In long-term BMT survivors the B cell compartment develops de novo and must regain its Table 2 Thyroid dysfunction in donor and recipient patients before and after bone marrow transplant. ontogeny. 20 In our patient, the development of thyroid autoimmunity 8 months after BMT could be related to transfer of abnormal donor clones and/or to development of new B cells capable of producing autoantibodies from marrow stem cells in response to antigens in the recipient.
Arguing against the possibility of transmission from the donor is the possibility of spontaneous development of autoimmune hypothyroidism in an individual at high risk of autoimmune thyroid disorders on a genetic basis. Because our patient's circulating lymphocytes were of donor origin, the only alternative explanation would be the persistence of its own intrathyroid lymphocyte population capable of producing the antibodies. However, this would seem very unlikely given the amount of chemotherapy and whole body irradiation that he had received. In addition, in this family, only the female donor and the recipient developed autoimmune thyroid disorders.
Other possible explanations to be considered are other causes of thyroid dysfunction following BMT not associated with autoimmune thyroid disorders. 21 Such dysfunction has been associated with radiation damage, viral infection or subacute thyroiditis secondary to chronic (GVHD). 21 Although our patient had received a high radiation dose (1200 cGy) and had signs of chronic GVHD at presentation, 6 months later when hypothyroidism developed, he had no signs of chronic GVHD. In addition, in these settings thyroid autoantibodies are usually negative, in contrast to the situation in our patient who had high titers of thyroid autoantibodies.
The term autoimmune thyroiditis has been redefined in recent years and can be viewed as a spectrum covering primary myxedema, Hashimoto thyroiditis and GD. Some patients with GD will later develop thyroid failure and some patients with Hashimoto thyroiditis will develop hyperthyroidism or orbitopathy. 6, 7 Among patients with GD who remain euthyroid after treatment, hypothyroidism, presumably due to chronic autoimmune thyroiditis or primary Bone Marrow Transplantation hypothyroidism caused by TSBAb, develops in about 10-20% after 10 to 25 years. 6, 7 In our report, the absence of goiter and the presence of TBII activity in the recipient point to atrophic hypothyroidism related to TSBAb and not to classical Hashimoto's thyroiditis, being the explanation of hypothyroidism. In addition, the donor developed transient hypothyroidism followed by hyperthyroidism with positive TBII, also suggesting TSBAb as the explanation of these phenomena.
In summary, this case demonstrates that autoimmune thyroid dysfunction after BMT can be transferred from the donor and present not only with the same symptoms but with a different clinical pattern. Anti-receptor antibodies directed against the TSH receptor may act not only as a TSH agonist causing thyrotoxicosis in the donor, but also as a TSH antagonist in the recipient, producing primary hypothyroidism.
